ArticleTranslational cancer research2025
Talin1 Ser425 phosphorylation promotes colorectal cancer progression and metastasis.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oncogenic role of talin-1 in glioma: Association with poor prognosis and regulation of the TGF-beta signaling pathway.Translational oncology · 2026Article
- The Duality of Cdk5: A Master Regulator in Neurodevelopment and a Hijacked Oncogene in Cancer.Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Talin1 serves as a crucial element within the multiprotein adhesion complexes that facilitate processes such as cell migration, adhesion, and integrin signaling. This study aimed to explore the underlying role of Talin1 Ser425 phosphorylation in the development of colorectal cancer (CRC). Methods: Blank plasmids, non-phosphorylatable mutant Talin1 S425A plasmids, and phosphorylation-mimetic mutant Talin1 S425D plasmids were constructed and used for transfection of CRC cells. The expression of mRNA and protein in CRC cells or tumor tissues was assessed by The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and UALCAN databases, immunohistochemistry (IHC), and Western blot (WB). Cell proliferation was assessed via 5-ethynyl-2-deoxyuridine (EDU) proliferation assay and colony formation assay. Cell migration and invasion were detected by wound healing assay and transwell assay. Cell apoptosis was assessed by flow cytometry. The Kaplan-Meier Plotter was used to evaluate the prognostic value of mRNA in CRC. Results: TLN1 was markedly downregulated in CRC tissues while the level of Talin1 Ser425 phosphorylation in CRC tissues and aggressive CRC cells was relatively higher. The S425A mutant inhibited CRC cell proliferation, migration, and invasion, whereas the S425D mutant promoted these processes. Flow cytometry assay showed that cell apoptosis was induced by S425A mutant and suppressed by S425D mutant in RKO cells. Further investigation suggested that CDK5 might be responsible for Talin1 phosphorylation. Conclusions: Talin1 Ser425 phosphorylation is of great importance in CRC development and Talin1 is supposed to be a potential tumor marker and therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.